Busulfan and Cyclophosphamide (Bu/Cy) as a Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma: A Single-Institution Experience

Jemal, 2004, Cancer statistics, 2004, CA Cancer J Clin, 54, 8, 10.3322/canjclin.54.1.8 Philip, 1995, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma, N Engl J Med, 333, 1540, 10.1056/NEJM199512073332305 Rohatiner, 2007, Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up, J Clin Oncol, 25, 2554, 10.1200/JCO.2006.09.8327 Schouten, 2003, High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP Trial, J Clin Oncol, 21, 3918, 10.1200/JCO.2003.10.023 Milpied, 2004, Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support, N Engl J Med, 350, 1287, 10.1056/NEJMoa031770 Tiwari, 2007, Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma, Bone Marrow Transplant, 40, 671, 10.1038/sj.bmt.1705795 Snyder, 1994, Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study, Bone Marrow Transplant, 14, 595 Kim, 2007, Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma, Bone Marrow Transplant, 40, 919, 10.1038/sj.bmt.1705841 Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403 Dey, 2007, Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen, Bone Marrow Transplant, 40, 19, 10.1038/sj.bmt.1705688 Spitzer, 2008, Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020, Biol Blood Marrow Transplant, 14, 59, 10.1016/j.bbmt.2007.03.014 Yusuf, 2008, Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma, Bone Marrow Transplant, 43, 37, 10.1038/bmt.2008.298 Fernandez, 2007, Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?, Bone Marrow Transplant, 40, 505, 10.1038/sj.bmt.1705744 Hanel, 2002, Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma, Ann Hematol, 81, 96, 10.1007/s00277-001-0413-8 Stein, 2000, Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate-grade non-Hodgkin's lymphoma, Bone Marrow Transplant, 25, 257, 10.1038/sj.bmt.1702132 Stiff, 1998, Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens. A Southwest Oncology Group trial, J Clin Oncol, 16, 48, 10.1200/JCO.1998.16.1.48 Wadhwa, 2005, High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality, Biol Blood Marrow Transplant, 11, 13, 10.1016/j.bbmt.2004.09.003 Aggarwal, 2006, Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen, Biol Blood Marrow Transplant, 12, 770, 10.1016/j.bbmt.2006.03.016 Ballester, 1996, Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery, Bone Marrow Transplant, 18, 9 Copelan, 2000, Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma, Bone Marrow Transplant, 25, 1243, 10.1038/sj.bmt.1702433 de Magalhaes-Silverman, 1997, Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma, Bone Marrow Transplant, 19, 777, 10.1038/sj.bmt.1700733 Schiffman, 1996, Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease, Bone Marrow Transplant, 17, 943 Weaver, 1998, High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma, Bone Marrow Transplant, 21, 383, 10.1038/sj.bmt.1701101 Zaucha, 2008, High-dose chemotherapy with BEAM or busulphan/melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma, Leuk Lymphoma, 49, 1899, 10.1080/10428190802340184 Diez-Martin, 2009, Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation, Blood, 113, 6011, 10.1182/blood-2008-12-195388 Fernandez, 2006